<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03992183</url>
  </required_header>
  <id_info>
    <org_study_id>TH-146</org_study_id>
    <nct_id>NCT03992183</nct_id>
  </id_info>
  <brief_title>Utility of CAML as Diagnostic for Early Stage Lung Cancer</brief_title>
  <official_title>TH-146: Cancer Associated Macrophage-Like (CAML) Cells to Enhance Detection of Early Stage Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fox Chase Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Creatv Microtech, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fox Chase Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective Determine the prevalence of CAMLS in patients with pulmonary nodules.

      Secondary Objectives Determine the positive and negative predictive value of CAMLS in
      patients with pulmonary nodules who undergo biopsy.

      Model combinations of clinical factors with the presence/absence of CAMLS to refine
      strategies for assessment of patients with pulmonary nodules. Evaluate whether these measures
      result in enhanced T-cell activity and/or NK cell function and number
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 21, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of prevalence pf CAMLs in Pulmonary modules</measure>
    <time_frame>During the first 2 years of study</time_frame>
    <description>Laboratory studies performed on blood drawn at Creatv Microtech will determine the prevalence of CAMLS in pulmonary nodules.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determination of positive and negative predictive value, sensitivity and specificity of CAMLS in patients with pulmonary nodules who undergo biopsy</measure>
    <time_frame>Through study completion, an average of 3 years</time_frame>
    <description>Positive Predictive Value and Negative Predictive Value, sensitivity and specificity at the initial screen will be computed for the entire study population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Model combinations of clinical factors with the presence/absence of CAMLs to refine strategies for assessment of patients with pulmonary nodules. Evaluate whether measures result in enhanced T-cell activity/Natural Killer (NK) cell function and number</measure>
    <time_frame>Through study completion, a maximum of 3 years</time_frame>
    <description>Bidimensional measurements of lung nodules done by a radiologist or pulmonary physician from CT scans with 5mm (or less) cuts, using lung windows in the axial plane</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Pulmonary Nodule, Multiple</condition>
  <condition>Pulmonary Nodule, Solitary</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Two 10cc of blood per draw
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects will be drawn from pulmonary nodule clinics at the Fox Chase Cancer Center and the
        VAMC Philadelphia
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Referral for a pulmonary nodule that has not yet been biopsied and that meets the
             definition of an &quot;indeterminate&quot; nodules (i.e. 0.8-3.0 cm).

          -  No prior diagnosis of lung cancer or other invasive malignancy within the past 5
             years.

          -  No history of rheumatologic disease.

          -  Age &gt; 18 years.

          -  Ability to understand and willingness to sign a written informed consent and HIPAA
             consent document

        Exclusion Criteria:

          -  Patients with active, known or suspected autoimmune disease.

          -  Prior diagnosis of lung cancer or other invasive malignancy within the past 5 years.

          -  Uncontrolled intercurrent illness that would increase the risk of toxicity or limit
             compliance with study requirements. This includes but is not limited to, uncontrolled
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  Known HIV-positive patients on combination antiretroviral therapy are ineligible
             because of the abnormal immune response that results from HIV disease (testing is not
             required).

          -  Patients should be excluded if they are known to be positive for hepatitis B virus
             surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody)
             indicating acute or chronic infection (testing is not required).

          -  Subjects with any history of interstitial lung disease or a history of &gt; or = to grade
             2 radiation pneumonitis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Martin J Edelman, MD</last_name>
    <phone>215-728-5682</phone>
    <email>martin.edelman@fccc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elizabeth V Gudesblat</last_name>
    <phone>215-214-1604</phone>
    <email>Elizabeth.Gudesblat@fccc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Corporal Michael J. Crescenz VA Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anil Vachani, MD, MD</last_name>
      <phone>215-573-7931</phone>
      <email>avachani@pennmedicine.upenn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin J Edelman, MD</last_name>
      <phone>215-728-5682</phone>
      <email>martin.edelman@fccc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Elizabeth V Gudesblat</last_name>
      <phone>215-214-1604</phone>
      <email>Elizabeth.Gudesblat@fccc.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 13, 2019</study_first_submitted>
  <study_first_submitted_qc>June 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2019</study_first_posted>
  <last_update_submitted>June 19, 2020</last_update_submitted>
  <last_update_submitted_qc>June 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CAML</keyword>
  <keyword>Early Detection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Pulmonary Nodules</mesh_term>
    <mesh_term>Solitary Pulmonary Nodule</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 26, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/83/NCT03992183/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

